Pharmacologic Vitreolysis with Ocriplasmin: Rationale for Use and Therapeutic Potential in Vitreo-Retinal Disorders.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 103, doi. 10.1007/s40259-015-0120-y
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2015 AND VI 29 AND IP 2
Results: 7
1
2
Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 113, doi. 10.1007/s40259-015-0121-x
- By:
- Publication type:
- Article
3
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 75, doi. 10.1007/s40259-015-0122-9
- By:
- Publication type:
- Article
4
Canakinumab: A Review of Its Use in the Management of Systemic Juvenile Idiopathic Arthritis.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 133, doi. 10.1007/s40259-015-0123-8
- By:
- Publication type:
- Article
5
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 123, doi. 10.1007/s40259-015-0124-7
- By:
- Publication type:
- Article
6
Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 143, doi. 10.1007/s40259-015-0125-6
- By:
- Publication type:
- Article
7
Erythrodermic Psoriasis: Current and Future Role of Biologicals.
- Published in:
- BioDrugs, 2015, v. 29, n. 2, p. 91, doi. 10.1007/s40259-015-0119-4
- By:
- Publication type:
- Article